Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944915 · ClinicalTrials.gov registry record · Phase 2
De-Escalation Therapy for Human Papillomavirus Negative Disease
A Phase 2 study of Squamous Cell Carcinoma and Squamous Cell Carcinoma of the Head and Neck, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03944915 is a Phase 2 study of Squamous Cell Carcinoma and Squamous Cell Carcinoma of the Head and Neck that has completed, run by University of Chicago. The registered enrollment target is 35 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03944915, a Phase 2 study of Squamous Cell Carcinoma and Squamous Cell Carcinoma of the Head and Neck, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the subject's cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Nivolumab
- DRUG Paclitaxel
- RADIATION Radiation
- DRUG Hydroxyurea Pill
Study Locations (1)
Illinois
- University Of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944915
The ClinicalTrials.gov registry entry for NCT03944915 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (66% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03944915 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03944915 about?
NCT03944915 is a clinical study titled "De-Escalation Therapy for Human Papillomavirus Negative Disease". This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the subject's cancer.
What is the current status of trial NCT03944915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2019-08-26. Estimated completion is 2023-11-01.
What conditions does trial NCT03944915 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus, HNSCC, HPV-Related Squamous Cell Carcinoma.
What interventions are being tested in trial NCT03944915?
The interventions under investigation include: Carboplatin (DRUG), Nivolumab (DRUG), Paclitaxel (DRUG), Radiation (RADIATION), Hydroxyurea Pill (DRUG).
Who is sponsoring clinical trial NCT03944915?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03944915 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
Explore more on PlainTrial
Squamous Cell Carcinoma
All registered trials for this condition
Squamous Cell Carcinoma of the Head and Neck
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.